Jim Cramer said on
CNBC's Mad Money that he was wrong on
Fitbit Inc (NYSE:
FIT), but he still likes it and wants to buy it. The stock is down 50 percent year to date, but people still think that it is expensive. He believes that the selling is overdone.
Cramer explained that Allergan plc Ordinary Shares (NYSE: AGN) is not trading higher because some people are speculating that the merger with Pfizer Inc. (NYSE: PFE) won't get through. He added that there is also a lot of scrutiny because of the tax aversion issue and that the stock is stagnating because the biotech space is currently out of favor.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
